Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

EUS-RFA PANCARDINAL-1 Trial

NCT: NCT04990609 · RECRUITING

NCT IDNCT04990609
StatusRECRUITING
Start Date2021-08-13
Completion2028-05-30
SponsorThe University of Texas Health Science Center, Houston (OTHER)
First posted
Last updated

Brief Summary

The objectives of this study are to determine the feasibility, tolerability, and treatment effect of endoscopic ultrasound (EUS) radiofrequency ablation (RFA) plus standard-of-care neoadjuvant chemotherapy (NAC) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound (EUS) radiofrequency ablation (RFA) and neoadjuvant chemotherapy (NAC) will be performed before tumor resection surgery, with the goal of shrinking a tumor or stopping the spread of cancer so that surgery might be less invasive and more effective.

Frequently Asked Questions

What is EUS-RFA PANCARDINAL-1 Trial?

EUS-RFA PANCARDINAL-1 Trial is a clinical trial registered under NCT04990609. Current status: RECRUITING.

What is the status of NCT04990609?

The current status of NCT04990609 (EUS-RFA PANCARDINAL-1 Trial) is: RECRUITING.

When did EUS-RFA PANCARDINAL-1 Trial start?

EUS-RFA PANCARDINAL-1 Trial started on 2021-08-13.

Related Devices

K203128EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME2/EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME2 PREMIER PLUSOlympus Medical Systems Corp. K191073Vein360 Endovenous Radiofrequency Ablation (RFA) CatheterVein 360, LLC K243502EVIS EUS ENDOSCOPIC ULTRASOUND CENTER OLYMPUS EU-ME3 (OLYMPUS EU-ME3)Olympus Medical Systems Corporation

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑